异基因移植治疗骨髓增生异常综合征和继发性急性髓系白血病后的晚期治疗相关死亡与竞争性死因
该回顾性研究基于EBMT数据纳入6434例接受首次异基因造血干细胞移植的成人骨髓增生异常综合征或继发性急性髓系白血病患者,采用标志点分析、相对生存法和多状态模型评估晚期死亡原因。移植后2年总生存率为53%,10年为35%;2年标志点后5年生存率在移植时<45岁患者为88%,≥65岁患者为63%。非复发死亡累积发生率在<45岁患者为7%,≥65岁患者为25%;老年患者中31%的非复发死亡可归因于人群死亡率。
要点
- 移植时年龄<45岁患者2年标志点后5年生存率为88%,≥65岁患者为63%。
- 非复发死亡累积发生率在<45岁患者为7%,≥65岁患者为25%。
- 老年患者中31%的非复发死亡可归因于人群死亡率。
核心结论
- 异基因造血干细胞移植后可见较好的长期生存,但所有年龄组与一般人群相比均显示超额死亡风险。
- 老年患者总非复发死亡的相当部分可归因于人群死亡率,该信息有助于平衡解释移植后风险并改善长期照护。
研究设计与样本
- 回顾性研究,使用EBMT数据纳入2000年1月至2012年12月期间接受首次异基因造血干细胞移植的6434例成人骨髓移植异常综合征或继发性急性髓系白血病患者。
- 采用联合标志点分析、相对生存法和多状态建模技术进行分析。
主要发现
- 移植时中位年龄从49岁增至58岁,移植时年龄≥65岁患者数量从5%增至17%。
- 移植后总生存概率2年为53%,10年为35%。
- 2年标志点后5年生存概率在移植时<45岁患者为88%,≥65岁患者为63%。
- 非复发死亡累积发生率在移植时<45岁患者为7%,≥65岁患者为25%。
- 老年患者中31%的非复发死亡可归因于人群死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.
引用
- Schetelig J, de Wreede LC, van Gelder M, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia. 2018. PMID: 30573777. doi:10.1038/s41375-018-0302-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。